Azathioprine (aza) or 6-mercaptopurine (6-mp) (DrugBank: Azathioprine, Mercaptopurine, 6-Mercaptopurine, 6-MP)
20 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
6 | Parkinson disease | 0 |
11 | Myasthenia | 0 |
13 | Multiple sclerosis/Neuromyelitis optica | 0 |
19 | Lysosomal storage disease | 0 |
35 | Pemphigus | 0 |
42 | Polyarteritis nodosa | 0 |
43 | Microscopic polyangiitis | 0 |
44 | Wegener granulomatosis | 0 |
45 | Eosinophilic granulomatosis with Polyangiitis | 0 |
46 | Malignant rheumatoid arthritis | 0 |
49 | Systemic lupus erythematosus | 0 |
63 | Idiopathic thrombocytopenic purpura | 0 |
65 | Primary immunodeficiency | 0 |
66 | IgA nephropathy | 0 |
85 | Idiopathic interstitial pneumonia | 0 |
94 | Primary sclerosing cholangitis | 0 |
95 | Autoimmune hepatitis | 0 |
96 | Crohn disease | 1 |
97 | Ulcerative colitis | 1 |
162 | Pemphigoid | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00521950 (ClinicalTrials.gov) | September 2007 | 27/8/2007 | Cost-effectiveness of TPMT Pharmacogenetics | Pharmacogenetic Testing in the Clinical Setting: is Screening for TPMT Genotype a Cost-effective Treatment Strategy? - The First Prospective Randomized Controlled Trial Within the Dutch Health Care System. | Inflammatory Bowel Diseases;Crohn Disease;Ulcerative Colitis | Genetic: TPMT genotyping; Drug: azathioprine or 6-mercaptopurine;Drug: azathioprine (AZA) or 6-mercaptopurine (6-MP) | ZonMw: The Netherlands Organisation for Health Research and Development | Radboud University | Completed | 18 Years | N/A | Both | 853 | N/A | Netherlands |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00521950 (ClinicalTrials.gov) | September 2007 | 27/8/2007 | Cost-effectiveness of TPMT Pharmacogenetics | Pharmacogenetic Testing in the Clinical Setting: is Screening for TPMT Genotype a Cost-effective Treatment Strategy? - The First Prospective Randomized Controlled Trial Within the Dutch Health Care System. | Inflammatory Bowel Diseases;Crohn Disease;Ulcerative Colitis | Genetic: TPMT genotyping; Drug: azathioprine or 6-mercaptopurine;Drug: azathioprine (AZA) or 6-mercaptopurine (6-MP) | ZonMw: The Netherlands Organisation for Health Research and Development | Radboud University | Completed | 18 Years | N/A | Both | 853 | N/A | Netherlands |